Wearable Injectors Market Expected to Reach US$ 26.94 Billion by 2031 | Growth Plus Reports

Newark, New Castle, USA, April 20, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Growth Plus Reports, the global wearable injectors market was valued at US$ 7.65 billion in 2022 and is expected to surpass US$ 26.94 billion by 2031, at a revenue CAGR of 15%. The report analyzes top winning strategies, drivers & opportunities, competitive scenarios, wavering market trends, market size, statistics & estimations, and major investment pockets.

Key Takeaways:

• The rising prevalence of oncological diseases will provide plenty of growth opportunities for the wearable injectors market.
• North America will dominate the global wearable injectors market.
• Increasing public awareness of the benefits of wearable injectors will fuel the growth of the wearable injectors market.

Request a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/wearable-injectors-market/8577

                                     Wearable Injectors Market Scope

Market Drivers

Innovative injector technology is the primary factor driving the revenue growth of the global market. Furthermore, the increasing prevalence of oncological diseases and cancer will support market revenue growth.

Market Segmentation

Growth Plus Reports has analyzed the global wearable injectors market from five perspectives: Type, Technology, Application, End User, and Region.

Type Segmentation: Based on the type, the global wearable injectors market is segmented into on-body, off-body devices. The on-body segment dominates the market with the largest revenue share because these patches are easy to put on the skin.

Technology Segmentation: Based on the technology, the global wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and others. The spring-base segment dominates the market with the largest revenue share because of its ease of use and patients' ability to accurately deliver the medicine subcutaneously by pressing one or more buttons on the device.

Application Segmentation: Based on the route of administration, the global wearable injector market is segmented into oncology, infectious disease, cardiovascular disease, autoimmune disease, and immunodeficiency. The oncology segment dominates the market with the largest revenue share because wearable injectors are becoming more popular in the healthcare business as cancer patients recognize the key advantages, such as reduced disease progression and suffering.

End User Segmentation: Based on the end-user, the global wearable injectors market is segmented into hospitals, clinics, home care & others. The home care segment dominates the market with the largest revenue share because of an increasing trend of decreasing hospital system strain.

Regional Growth Dynamics

Based on the region, the global wearable injectors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the global wearable injectors market due to The European region is expected to register significant revenue growth because of the government's active support, greater interest in drug development, and the rising prevalence of Parkinson's and Alzheimer's disease in this region.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/wearable-injectors-market/8577

Competitive Landscape

The major players operating in the global wearable injectors market are:

• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Unilife Corporation
• Steady Med Therapeutics Inc.
• Insulet Corporation
• Sensile Medical
• Johnson & Johnson Services Inc.
• Amgen Inc.
• Dexcom Inc.
• CeQur SA
• Enable Injections
• Tandem Diabetes Care Inc.
• Ypsomed
• West Pharmaceutical Services Inc.

The wearable injectors market is moderately competitive with few key players. Key players operating in the market are implementing competitive sustainability tactics such as product development and regional presence growth. Major firms are aggressively acquiring other companies to strengthen their global market positions.

Recent developments:

• The US Food and Drug Administration authorized SKYRIZI (risankizumab-rzaa) in June 2022 as the first and only selective interleukin-23 (IL-23) inhibitor for the treatment of persons with moderately to highly active Crohn's disease. (CD). Subcutaneous Injection (SC) with an On-Body Injector (OBI) is a method of self-administration.
• Enable Injections secured a USD 215 million round in February 2022 to support the development of the enFuse subcutaneous drug delivery system. The device includes a wearable delivery disc and a technique for transferring medicine from its original vessel.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Products
      1. Secondary Products 
      2. Primary Products 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL WEARABLE INJECTORS MARKET- ANALYSIS & FORECAST, BY TYPE
   1. On- body
   2. Off-body
6. GLOBAL WEARABLE INJECTORS MARKET- ANALYSIS & FORECAST, BY TECHNOLOGY
   1. Spring-Based
   2. Motor-Driven
   3. Rotary Pump 
   4. Expanding Battery
   5. Other
7. GLOBAL WEARABLE INJECTORS MARKET- ANALYSIS & FORECAST, BY APPLICATION
   1. Oncology
   2. Infectious Disease
   3. Cardiovascular Disease 
   4. Autoimmune Disease
   5. Immunodeficiency
8. GLOBAL WEARABLE INJECTORS MARKET- ANALYSIS & FORECAST, BY END-USER
   1. Hospitals
   2. Clinics
   3. Home Care
   4. Others

WEARABLE INJECTORS MARKET TOC

Buy this Premium Research Report:  https://www.growthplusreports.com/checkout-8577

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse Latest Healthcare Related Reports:

Dry Powder Inhalers Market by Product Type (Single Dose Dry Powder Inhaler, Multi Dose Dry Powder Inhaler), Application (Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Drug Stores)– Global Outlook & Forecast 2023-2031

Diabetic Neuropathy Market by Disorder (Peripheral Neuropathy, Autonomic Neuropathy), Drug Class (Analgesic, Antidepressant) - Global Outlook and Forecast 2023-2031

Hypertension Drugs Market by Drug Class (Beta Blockers, Diuretics), Distribution Channel (Hospital Pharmacies, Online Pharmacies) – Global Outlook & Forecast 2023-2031

Operating Room Integration Market by Component (Software, Services), Application General Surgery, Orthopedic Surgery), Device Type (Audio-Video Management System, Display System), End User (Hospitals, Ambulatory Surgery Centers) – Global Outlook & Forecast 2023-2031

Cardiology Stem Cells Market by Types of Cells (Embryonic Stem Cells, Cord Blood Stem Cells, and Amniotic Fluid Stem Cells), Source (Autologous, Allogenic), Application (Heart Failure, Myocardial Infarction), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes) - Global Outlook and Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.